KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Income (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 15 years of Net Income data on record, last reported at $208.5 million in Q4 2025.

  • For Q4 2025, Net Income rose 9.07% year-over-year to $208.5 million; the TTM value through Dec 2025 reached -$509.9 million, down 190.77%, while the annual FY2025 figure was -$355.5 million, 163.27% down from the prior year.
  • Net Income reached $208.5 million in Q4 2025 per JAZZ's latest filing, up from -$718.4 million in the prior quarter.
  • Across five years, Net Income topped out at $215.3 million in Q3 2024 and bottomed at -$718.4 million in Q2 2025.
  • Average Net Income over 5 years is -$4.1 million, with a median of $53.8 million recorded in 2022.
  • Peak YoY movement for Net Income: tumbled 641.54% in 2022, then skyrocketed 1116.53% in 2023.
  • A 5-year view of Net Income shows it stood at -$32.4 million in 2021, then crashed by 641.54% to -$240.0 million in 2022, then soared by 139.43% to $94.6 million in 2023, then soared by 101.99% to $191.1 million in 2024, then increased by 9.07% to $208.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were $208.5 million in Q4 2025, -$718.4 million in Q2 2025, and $191.1 million in Q4 2024.